UroGen Pharma (LTS:0XOD) Stock Based Compensation: $13.5 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0XOD UroGen Pharma Ltd LTS:0XOD
52 GF Score
Price $38.60
GF Value $22.63
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is UroGen Pharma Stock Based Compensation?

UroGen Pharma LTS:0XOD -5.55% 52 Stock Based Compensation is $13.5 Mil as of Mar. 2026. GuruFocus rates LTS:0XOD with a GF Score™ of 52/100 and a GF Value™ of $22.63 (Significantly Overvalued). The stock has 10 warning signs investors should review.

UroGen Pharma's Stock Based Compensation for the three months ended in Mar. 2026 was $4.6 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $13.5 Mil.

UroGen Pharma Stock Based Compensation Related Terms

UroGen Pharma Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for UroGen Pharma's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UroGen Pharma Stock Based Compensation Chart

UroGen Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.11 10.58 9.34 13.11 11.96

UroGen Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.07 2.73 3.03 3.13 4.63
LTS:0XOD
52GF Score
UroGen Pharma Ltd LTS:0XOD
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

UroGen Pharma Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.5 Mil.

What does a Stock Based Compensation of $13.5 Mil mean?
UroGen Pharma (LTS:0XOD) has a Stock Based Compensation of $13.5 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for UroGen Pharma and its competitors.
Is UroGen Pharma's Stock Based Compensation too high?
UroGen Pharma's current Stock Based Compensation is $13.5 Mil. Overall, UroGen Pharma has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UroGen Pharma's Stock Based Compensation compare to PVLA and AUPH?
UroGen Pharma's Stock Based Compensation of $13.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for UroGen Pharma and its competitors. UroGen Pharma's current Stock Based Compensation is $13.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UroGen Pharma stock overvalued right now?
Based on GuruFocus' analysis, UroGen Pharma (LTS:0XOD) is currently considered Significantly Overvalued. The stock's GF Value™ is $22.63, compared to a current price of $38.60 — trading 70.6% above its estimated fair value. The current Stock Based Compensation is $13.5 Mil. UroGen Pharma's overall GF Score™ is 52/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For UroGen Pharma (LTS:0XOD), the current Stock Based Compensation is $13.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UroGen Pharma (LTS:0XOD) Overvalued in 2026?

Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued. The current stock price of $38.60 is trading 70.6% above its estimated GF Value™ of $22.63. GuruFocus considers UroGen Pharma to be Significantly Overvalued.

Key valuation signals for LTS:0XOD:

  • Stock Based Compensation: $13.5 Mil
  • GF Value™: $22.63 vs. price of $38.60 (70.6% above fair value)
  • GF Score™: 52/100 with 10 warning signs

No single metric tells the full story. See the LTS:0XOD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UroGen Pharma Business Description

Other Exchanges URGN:USAUR8:Germany
Address 400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
52GF Score

Get the complete analysis for LTS:0XOD

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$38.60
Price
$22.63
GF Value